Baxter Hlthcare Corp Company Profile

« Back to Dashboard

What is the competitive landscape for BAXTER HLTHCARE CORP

BAXTER HLTHCARE CORP has eighty-one approved drugs.

There are twenty-six US patents protecting BAXTER HLTHCARE CORP drugs. There are two tentative approvals on BAXTER HLTHCARE CORP drugs.

Summary for Baxter Hlthcare Corp

US Patents:	26
Tradenames:	78
Ingredients:	65
NDAs:	81

Drugs and US Patents for Baxter Hlthcare Corp

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare Corp	REGADENOSON	regadenoson	SOLUTION;INTRAVENOUS	217455-001	May 23, 2023	AP	RX	No	No
Baxter Hlthcare Corp	LEVETIRACETAM IN SODIUM CHLORIDE	levetiracetam	INJECTABLE;INTRAVENOUS	217059-001	Oct 2, 2023	AP	RX	No	No
Baxter Hlthcare Corp	GRANISETRON HYDROCHLORIDE	granisetron hydrochloride	INJECTABLE;INJECTION	078197-001	Dec 31, 2007		DISCN	No	No
Baxter Hlthcare Corp	SUCCINYLCHOLINE CHLORIDE	succinylcholine chloride	INJECTABLE;INJECTION	218878-001	Sep 24, 2024	AP	RX	No	No
Baxter Hlthcare Corp	EPHEDRINE SULFATE	ephedrine sulfate	SOLUTION;INTRAVENOUS	216740-001	Jul 8, 2026	AP	RX	No	No
Baxter Hlthcare Corp	NOURESS	cysteine hydrochloride	SOLUTION;INTRAVENOUS	212535-001	Dec 13, 2019		RX	Yes	Yes	10,905,713		Y
Baxter Hlthcare Corp	PHENYLEPHRINE HYDROCHLORIDE	phenylephrine hydrochloride	SOLUTION;INTRAVENOUS	217032-002	Apr 3, 2026	AP1	RX	No	No

Expired US Patents for Baxter Hlthcare Corp

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Baxter Hlthcare Corp	ZOSYN IN PLASTIC CONTAINER	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050750-003	Feb 24, 1998	6,207,661
Baxter Hlthcare Corp	TRANSDERM SCOP	scopolamine	SYSTEM;TRANSDERMAL	017874-001	Approved Prior to Jan 1, 1982	4,031,894
Baxter Hlthcare Corp	CLINOLIPID 20%	olive oil; soybean oil	EMULSION;INTRAVENOUS	204508-001	Oct 3, 2013	5,840,757
Baxter Hlthcare Corp	DOXIL (LIPOSOMAL)	doxorubicin hydrochloride	INJECTABLE, LIPOSOMAL;INJECTION	050718-002	Jun 13, 2000	5,013,556
Baxter Hlthcare Corp	ZOSYN IN PLASTIC CONTAINER	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050750-002	Feb 24, 1998	6,900,184
Baxter Hlthcare Corp	ZOSYN IN PLASTIC CONTAINER	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050750-003	Feb 24, 1998	8,133,883
Baxter Hlthcare Corp	TRANSDERM SCOP	scopolamine	SYSTEM;TRANSDERMAL	017874-001	Approved Prior to Jan 1, 1982	4,436,741

International Patents for Baxter Hlthcare Corp Drugs

Country	Patent Number	Estimated Expiration
Poland	3554474
Spain	2972008
Canada	3170514
China	115243675
Brazil	112022015170
Finland	3554474
Australia	2021233893

Supplementary Protection Certificates for Baxter Hlthcare Corp Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2666774	LUC00167	Luxembourg		PRODUCT NAME: RELEBACTAM, EVENTUELLEMENT SOUS FORME DE MONOHYDRATE, IMIPENEME ET CILASTATINE, EVENTUELLEMENT SOUS FORME DE SEL DE SODIUM; AUTHORISATION NUMBER AND DATE: EU/1/19/1420 20200217
0984957	C300483	Netherlands		PRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMTRIHYFRAAT; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17091/0263 - 0001 20110524
2785706	C02785706/01	Switzerland		PRODUCT NAME: FOSNETUPITANT, PALONOSETRON.; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68290 01.09.2022
2666774	202040029	Slovenia		PRODUCT NAME: RELEBACTAM, OPTIONALLY IN THE FORM OF MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF SODIUM SALT; NATIONAL AUTHORISATION NUMBER: EU/1/19/1420; DATE OF NATIONAL AUTHORISATION: 20200213; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2673237	201940014	Slovenia		PRODUCT NAME: SODIUM ZIRCONIUM CYCLOSILICATE; NATIONAL AUTHORISATION NUMBER: EU/1/17/1173; DATE OF NATIONAL AUTHORISATION: 20180322; AUTHORITY FOR NATIONAL AUTHORISATION: EU
1115417	SPC/GB06/024	United Kingdom		SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB06/024 GRANTED TO CUBIST PHARMACEUTICALS, INC IN RESPECT OF THE PRODUCT DAPTOMYCIN, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6162 DATED 27 JUNE 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 22 JANUARY 2021.
3494972	202440019	Slovenia		PRODUCT NAME: DOLUTEGRAVIR OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING SODIUM DOLUTEGRAVIR, AND LAMIVUDINE; NATIONAL AUTHORISATION NUMBER: EU/1/19/1370; DATE OF NATIONAL AUTHORISATION: 20190701; AUTHORITY FOR NATIONAL AUTHORISATION: EU

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Baxter Hlthcare
• Baxter Hlthcare Corp